<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>sleep apnea &#8211; Pharmacy Update Online</title>
	<atom:link href="https://pharmacyupdateonline.com/tag/sleep-apnea/feed/" rel="self" type="application/rss+xml" />
	<link>https://pharmacyupdateonline.com</link>
	<description></description>
	<lastBuildDate>Thu, 11 May 2023 14:23:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://pharmacyupdateonline.com/wp-content/uploads/2020/12/cropped-favicon-512x360.png</url>
	<title>sleep apnea &#8211; Pharmacy Update Online</title>
	<link>https://pharmacyupdateonline.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Sleep apnea associated with increased risk for long COVID</title>
		<link>https://pharmacyupdateonline.com/2023/05/sleep-apnea-associated-with-increased-risk-for-long-covid/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Sat, 13 May 2023 08:00:34 +0000</pubDate>
				<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Medicines and Therapeutics]]></category>
		<category><![CDATA[covid]]></category>
		<category><![CDATA[covid-19]]></category>
		<category><![CDATA[Long COVID]]></category>
		<category><![CDATA[Polysomnography]]></category>
		<category><![CDATA[sleep apnea]]></category>
		<guid isPermaLink="false">https://www.pharmacyupdate.online/?p=8893</guid>

					<description><![CDATA[Sleep apnea may significantly increase the risk for long COVID in adults, according to a study led by the National Institutes of Health’s RECOVER Initiative and supported by NYU Langone [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>Sleep apnea may significantly increase the risk for long COVID in adults, according to a study led by the <a href="https://recovercovid.org/">National Institutes of Health’s RECOVER Initiative</a> and supported by NYU Langone Health as home to the effort’s Clinical Science Core (CSC).</p>
<p>As of<strong> </strong>April 2023,<strong> </strong>more than 100 million Americans had been infected with the virus that causes COVID-19. As of April the U.S. <a href="https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm">Government’s Household Pulse survey estimated that about 6 percent of U.S. adults are experiencing</a> symptoms associated with long COVID, including brain fog, fatigue, depression, and sleep problems. Past studies have shown that patients with obstructive sleep apnea (OSA) tend to have more severe illness when initially infected with COVID-19. OSA affects about <a href="https://www.cdc.gov/pcd/issues/2021/21_0305.htm#T1_down">1 in 8</a> adults but is often underdiagnosed.</p>
<p>To better understand links between sleep apnea and long-term COVID symptoms, the research team reviewed data across three RECOVER research networks of patients who had tested positive for COVID-19 between March 2020 and February 2022, according to their health records. Two networks included adult patients – the National Patient-Centered Clinical Research Network (PCORnet) with 330,000 patients – and the National COVID Cohort Collaborative (N3C) with 1.7 million patients. The third patient cohort in the study analysis included the pediatric-focused network PEDSnet, made up of 102,000 children.</p>
<p>Published online on May 11 in the journal <em>Sleep,</em> this study found that a prior diagnosis of sleep apnea in the PCORnet group came with a 12 percent increase in risk for long-term symptoms months after patients’ initial infections. In the N3C patient group, in which patients had higher levels of other chronic conditions than those in PCORnet, sleep apnea came with a 75 percent increase in risk for long COVID compared to those without sleep apnea. The observed increases in risk for long COVID in adults with sleep apnea remained significant even when the research team accounted for obesity, hypertension, diabetes, and hospitalization at the time of their initial COVID infection, all known to independently contribute to risk for long COVID.</p>
<p>The researchers hypothesize that the differences in the percentage increases in long COVID risk between the study groups may be further explained by variations in <a href="https://pubmed.ncbi.nlm.nih.gov/33791733/">definitions</a> of long COVID, study populations, and in analysis methods of patient records, across the large study. In contrast to the patterns seen in adults, the contribution of sleep apnea to the risk of long COVID disappeared in children when the researchers controlled for other risk factors, including obesity.</p>
<p>“A strength of the work is that the link between sleep apnea and long COVID persisted regardless of how the researchers in our study defined long COVID or gathered data<strong>,”</strong> says senior study author Lorna Thorpe, PhD, MPH, Professor and Director of the Division of Epidemiology at NYU Langone Health. She is also co-lead of efforts to understand long COVID using electronic health record networks for the RECOVER CSC at NYU Langone. “This study is the first collaboration of this focus and scale to find that adults with sleep apnea are at greater risk for long COVID.”</p>
<p>RECOVER—Researching COVID to Enhance Recovery—is dedicated to understanding why some people develop long-term symptoms following a COVID infection, and how to detect, treat, and prevent long COVID. As the CSC, NYU Langone Health is charged with integrating research activities of clinical sites around the country.</p>
<p>“There’s still so much to uncover about long COVID, but this study will inform clinical care by identifying patients that should be watched more closely,” says corresponding author Hannah Mandel, a senior research scientist for the electronic health record studies arm of the RECOVER CSC at NYU Langone Health. “People with sleep apnea who get infected with COVID should seek early treatment, pay attention to their symptoms, and keep up with their vaccinations to lower the risk of infection in the first place.”</p>
<p>Interestingly, in the N3C study group, long COVID risk was higher among women with sleep apnea compared to men with sleep apnea. Investigators identified an 89% increased likelihood for having long COVID in women, compared to a 59% increased chance for men. The reasons for this are not clear, but <a href="https://www.nhlbi.nih.gov/health/sleep-apnea/women">women</a> with diagnosed sleep apnea in their medical records may have more severe conditions than men, in part because women with sleep apnea tend to go undiagnosed with OSA for longer.</p>
<p>The study was funded by RECOVER (<a href="https://reporter.nih.gov/search/abjdRAUnkEyTTannvkvhTw/projects">OT2HL161847</a>) and received additional support from the National Center for Advancing Translational Sciences (<a href="https://reporter.nih.gov/search/65UpeQpW9kaDO0Bkk_ZF0g/projects">UL1TR002494</a>). For more information on RECOVER, visit <a href="https://recovercovid.org/">https://recovercovid.org</a>. In addition, the CSC at NYU Langone Health is co-led by RECOVER co-principal investigators <a href="https://nyulangone.org/doctors/1306834478/stuart-d-katz" target="_blank" rel="noopener">Stuart D. Katz, MD</a>, Helen L. and Martin S. Kimmel Professor of Advanced Cardiac Therapeutics and founding director of NYU Langone’s heart failure program; <a href="https://nyulangone.org/doctors/1841334810/leora-horwitz" target="_blank" rel="noopener">Leora Horwitz, MD</a>, director of the <a href="https://med.nyu.edu/centers-programs/healthcare-innovation-delivery-science" target="_blank" rel="noopener">Center for Healthcare Innovation and Delivery Science</a>; <a href="https://med.nyu.edu/faculty/andrea-b-troxel">Andrea B. Troxel, ScD</a>, director of the <a href="https://med.nyu.edu/departments-institutes/population-health/divisions-sections-centers/biostatistics">Division of Biostatistics </a>and professor in the <a href="https://med.nyu.edu/departments-institutes/population-health">Department of Population Health</a>; and <a href="https://med.nyu.edu/faculty/rachel-s-gross">Rachel S. Gross, MD</a>, director of pediatric research for RECOVER CSC and assistant professor of pediatrics and population health at the <a href="https://med.nyu.edu/">NYU Grossman School of Medicine</a> and Bellevue Hospital Center.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Promising medication for sleep apnea</title>
		<link>https://pharmacyupdateonline.com/2022/10/promising-medication-for-sleep-apnea/</link>
		
		<dc:creator><![CDATA[Charlie King]]></dc:creator>
		<pubDate>Wed, 12 Oct 2022 08:00:57 +0000</pubDate>
				<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Medicines and Therapeutics]]></category>
		<category><![CDATA[continuous positive airway pressure]]></category>
		<category><![CDATA[oxybutynin]]></category>
		<category><![CDATA[Pharmacology]]></category>
		<category><![CDATA[Polysomnography]]></category>
		<category><![CDATA[reboxetine]]></category>
		<category><![CDATA[sleep apnea]]></category>
		<guid isPermaLink="false">https://www.pharmacyupdate.online/?p=5266</guid>

					<description><![CDATA[Targeting a condition suffered by nearly a billion people worldwide, a new study from Flinders University has shown a drug previously used to treat depression can reduce obstructive [&#8230;]]]></description>
										<content:encoded><![CDATA[<p id="first" class="lead">Targeting a condition suffered by nearly a billion people worldwide, a new study from Flinders University has shown a drug previously used to treat depression can reduce obstructive sleep apnoea (OSA) severity.</p>
<div id="text">
<p>While not yet identifying a cure, the authors say the study opens up further avenues for the development of future drug treatments targeted at the huge number of people unable to tolerate current sleep apnoea therapies, such as continuous positive airway pressure (CPAP) machines.</p>
<p>&#8220;Obstructive sleep apnoea can be a debilitating disease, causing poor quality sleep at night and sleepiness during the day,&#8221; says study lead author Dr Thomas Altree from FHRMI: Sleep Health (formerly the Adelaide Institute for Sleep Health).</p>
<p>&#8220;It affects millions of Australians and causes major impacts on health and productivity.</p>
<p>&#8220;Recent research found a combination of the medicines reboxetine and oxybutynin, which were both previously used for unrelated conditions, could be an effective treatment for obstructive sleep apnoea but can cause side effects.</p>
<p>&#8220;We wanted to see if reboxetine on its own could be effective and assess exactly how it changes breathing during sleep.&#8221;</p>
<p>The team ran a double blind, placebo controlled, randomised, multicentre cross-over trial with collaborators at the Woolcock Institute in Sydney (following a gold standard for drug trials) with 16 people who had OSA. They tested single doses of reboxetine compared to a combination of reboxetine and oxybutynin or placebo.</p>
<p>&#8220;Our results showed that reboxetine on its own can reduce sleep apnoea severity,&#8221; says Dr Altree.</p>
<p>&#8220;We found the drug reduced the number of sleep apnoea events per hour and also improved oxygen levels, while the addition of oxybutynin didn&#8217;t cause additional improvements.</p>
<p>&#8220;We also used a state-of-the-art computing method to determine how the drug stabilises breathing during sleep, which allows us to identify which patients might benefit most from the drug in the future.&#8221;</p>
<p>The team&#8217;s findings present the first evidence that reboxetine alone reduces OSA severity, and provides further insight into the role of norepinephrine reuptake inhibitors on upper airway stability during sleep.</p>
<p>&#8220;The current gold-standard treatment of sleep apnoea is with a CPAP device during sleep. But this one-size-fits-all approach doesn&#8217;t address the fact that there are different causes for sleep apnoea. In addition, many people can&#8217;t tolerate CPAP in the long term,&#8221; says Dr Altree.</p>
<p>&#8220;It&#8217;s therefore important we discover other avenues to assist people, and this study provides an important step for future drug development.&#8221;</p>
<p><strong>Journal Reference</strong>:</p>
<ol class="journal">
<li>Thomas J. Altree, Atqiya Aishah, Kelly A. Loffler, Ronald R. Grunstein, Danny J. Eckert. <strong>The norepinephrine reuptake inhibitor reboxetine alone reduces obstructive sleep apnea severity: a double blind, placebo controlled, randomized, cross-over trial</strong>. <em>Journal of Clinical Sleep Medicine</em>, 2022; DOI: <a href="http://dx.doi.org/10.5664/jcsm.10256" target="_blank" rel="noopener noreferrer nofollow">10.5664/jcsm.10256</a></li>
</ol>
</div>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Treating sleep apnea may reduce dementia risk</title>
		<link>https://pharmacyupdateonline.com/2021/04/treating-sleep-apnea-may-reduce-dementia-risk/</link>
		
		<dc:creator><![CDATA[Alex Burton]]></dc:creator>
		<pubDate>Sun, 18 Apr 2021 12:16:28 +0000</pubDate>
				<category><![CDATA[Medicines and Therapeutics]]></category>
		<category><![CDATA[Alzheimers]]></category>
		<category><![CDATA[dementia]]></category>
		<category><![CDATA[sleep apnea]]></category>
		<guid isPermaLink="false">https://www.pharmacyupdate.online/?p=624</guid>

					<description><![CDATA[A new study finds older adults who received positive airway pressure therapy prescribed for obstructive sleep apnea may be less likely to develop Alzheimer&#8217;s disease and other kinds [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>A new study finds older adults who received positive airway pressure therapy prescribed for obstructive sleep apnea may be less likely to develop Alzheimer&#8217;s disease and other kinds of dementia.</p>
<p>Researchers from Michigan Medicine&#8217;s Sleep Disorders Centers analyzed Medicare claims of more than 50,000 Medicare beneficiaries ages 65 and older who had been diagnosed with OSA. In this nationally representative study, they examined if those people who used positive airway pressure therapy were less likely to receive a new diagnosis of dementia or mild cognitive impairment over the next 3 years, compared to people who did not use positive airway pressure.</p>
<p>&#8220;We found a significant association between positive airway pressure use and lower risk of Alzheimer&#8217;s and other types of dementia over three years, suggesting that positive airway pressure may be protective against dementia risk in people with OSA,&#8221; says lead author Galit Levi Dunietz, Ph.D., M.P.H., an assistant professor of neurology and a sleep epidemiologist.</p>
<p>The findings stress the impact of sleep on cognitive function. &#8220;If a causal pathway exists between OSA treatment and dementia risk, as our findings suggest, diagnosis and effective treatment of OSA could play a key role in the cognitive health of older adults,&#8221; says study principal investigator Tiffany J. Braley, M.D., M.S., an associate professor of neurology.</p>
<p>Obstructive sleep apnea is a condition in which the upper airway collapses repeatedly throughout the night, preventing normal breathing during sleep. OSA is associated with a variety of other neurological and cardiovascular conditions, and many older adults are at high risk for OSA.</p>
<p>And dementia is also prevalent, with approximately 5.8 million Americans currently living with it, Braley says.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
